Amyris Bundle
Who owns Amyris now?
Amyris began in 2003 to engineer yeast for sustainable molecules and later built consumer brands before Chapter 11 in August 2023 shifted control toward creditors and asset buyers. The bankruptcy and subsequent sales transformed ownership from diluted public equity to creditor-driven stakeholders.
Post-bankruptcy, control moved from public shareholders and founders to secured creditors, restructuring stakeholders, and buyers of consumer assets; key shifts involved debt-for-equity swaps and sales of brands like Biossance. See Amyris Porter's Five Forces Analysis for strategic context.
Who Founded Amyris?
Amyris was founded in 2003 by Jay D. Keasling, Jack D. Newman, Kinkead Reiling, Neil A. Renninger and Paul F. Alspaugh; early ownership concentrated among the five founders and initial technical team, with academic IP licensed from UC Berkeley/LBNL and artemisinin work funded by the Bill & Melinda Gates Foundation.
Founding team
Five founders held the lion's share of early equity; technical leadership tied to Keasling's artemisinin project.
Academic IP
IP assignments and licenses flowed from UC Berkeley and LBNL under standard university licensing pathways.
Early grant support
The Bill & Melinda Gates Foundation funded artemisinin development efforts that seeded early technical progress.
Venture backers
Khosla Ventures and Kleiner Perkins were notable early investors and participated in pre-IPO financings in the 2000s.
Equity structure
Typical venture-era terms included four-year vesting with one-year cliffs, convertible instruments, preferred rounds and IP assignment clauses.
Dilution over time
Founder operational roles and direct ownership were substantially diluted by repeated capital raises and preferred financings through the 2010s.
Early financing set liquidation preferences and anti-dilution protections that later influenced control; no major founder legal disputes were widely reported in the initial phase.
Key early ownership facts
Founders, early employees and institutional backers shaped the initial cap table and subsequent dilution dynamics.
- Founders: Jay D. Keasling, Jack D. Newman, Kinkead Reiling, Neil A. Renninger, Paul F. Alspaugh
- Early grant: Bill & Melinda Gates Foundation for artemisinin development
- Venture investors: Khosla Ventures, Kleiner Perkins (pre-IPO rounds)
- Structural terms: convertible securities, preferred stock with liquidation preferences and anti-dilution clauses
For more on competitive positioning and investor context, see Competitors Landscape of Amyris
Amyris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Amyris’s Ownership Changed Over Time?
Key events — VC-led preferred stacks pre-2010, the 2010 IPO, strategic JV and financing rounds (2013–2019), heavy equity and convertible financings (2020–2022), and the August 2023 Chapter 11 — materially shifted Amyris ownership, leaving secured creditors and asset buyers dominant by 2024–2025.
| Period | Primary Stakeholders | Ownership Impact |
|---|---|---|
| Pre-2010 | Khosla Ventures, Kleiner Perkins, other VCs | Preferred stacks, board seats, anti-dilution provisions |
| 2010 IPO | Institutional & retail investors (NASDAQ: AMRS) | Market cap in the several hundred million range; broadened public float; dilution via secondaries |
| 2013–2019 | Total/TotalEnergies, DSM, Givaudan-linked counterparties | Warrants, preferreds, revenue-share deals altered economic rights and cap table complexity |
| 2020–2022 | Institutional investors, retail holders | Large equity and convertible debt financings; liabilities rose; insider ownership remained modest |
| Aug 2023 (Chapter 11) | Secured lenders, DIP financiers | Ownership primacy shifted to creditors; equity deeply impaired |
| 2023–2024 | Asset buyers, strategic/financial acquirers | Section 363 sales (e.g., Biossance) transferred brand ownership; proceeds for creditor recovery |
By mid‑2024–2025, Amyris ownership resembled a creditor-controlled restructuring: secured lenders and DIP financiers directed outcomes, buyers owned divested consumer brands, and any residual reorganized shell left legacy public shareholders largely wiped out or highly diluted; for background, see Brief History of Amyris.
Ownership inflection points
Major stages reshaped who owns Amyris: VC control, public float expansion, strategic JV complexities, heavy 2020s financings, and creditor-led restructuring after 2023.
- Pre‑2010 VCs established preferred protections and board representation
- 2010 IPO broadened Amyris shareholders but later diluted early holders
- 2013–2019 strategic deals added warrants/preferreds changing economic rights
- 2023 bankruptcy shifted control to secured lenders and asset acquirers
Amyris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Amyris’s Board?
As of mid-2025 the board of the reorganized company reflects creditor and independent nominations with few legacy founder representatives; composition emphasizes restructuring, commercial and capital-markets expertise and includes directors selected under the confirmed Chapter 11 plan.
| Director | Background | Nomination Source |
|---|---|---|
| Independent Financial Expert | Capital markets, restructurings | Creditor-nominated |
| Consumer Products Executive | Brand and commercial operations | Independent committee |
| Restructuring Attorney | Bankruptcy and insolvency | Bankruptcy court approval |
Pre-bankruptcy governance featured a one-share-one-vote common stock regime without dual-class supervoting, which meant founder influence declined over time and ownership was vulnerable to dilution once insolvency pressures rose.
Board control during Chapter 11
Practical control shifted from the incumbent board to debtor-in-possession lenders, the bankruptcy court, and an independent special committee overseeing budgets, asset sales and plan terms.
- Budget approvals and cash collateral controlled by DIP lenders
- Asset sales and stalking-horse bids approved through court-supervised process
- Creditor-nominated directors typically installed under confirmed plans
- Legacy shareholders’ voting power reduced to de minimis post-emergence
Key 2024–2025 facts: the company operated under DIP financing that prioritized lender claims; proxy contests were effectively replaced by court-ordered negotiations; post-confirmation equity allocations in similar cases often leave prior common shareholders with less than 1% of reorganized equity or only warrants—precise percentages depend on the confirmed plan and disclosure statement.
For further context on strategy and ownership shifts see Growth Strategy of Amyris
Amyris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Amyris’s Ownership Landscape?
Between 2023 and 2025 Amyris ownership shifted from public equity to creditor and strategic control after a Chapter 11 filing and asset dispositions, leaving legacy Amyris shareholders with minimal recovery and new equity likely held by creditor groups or buyers of IP and brands.
| Event | Timing | Ownership impact |
|---|---|---|
| Chapter 11 filing | August 2023 | Economic value reallocated to creditors; public equity largely wiped out per absolute-priority rules |
| 363 brand and asset sales | Late 2023–2024 | Consumer brands sold at auction; proceeds prioritized creditors and buyers received IP/brands |
| Licensing of fermentation assets/IP | 2023–2024 | Strategic buyers acquired molecule IP or licenses; company shifted toward asset-light model |
| Leadership and board changes | 2023–2024 | Management turnover and board refresh under creditor-led restructuring |
Industry context: rising cost of capital (2022–2024) and capital-intensive scale-up led to dilution of founders and VCs across synthetic biology, with institutional equity shrinking as firms delisted or recapitalized while private credit and strategic corporates increased ownership influence.
Ownership outcome after restructuring
Reorganized entity or successor vehicle is expected to be privately controlled by creditor groups with new equity issued to satisfy claims; legacy shareholders likely hold negligible positions.
Public trading outlook
No credible guidance by 2025 points to near-term relisting; analysts view public float restoration as unlikely without a fresh capital raise or reverse merger.
Implications for Amyris shareholders
Per standard Chapter 11 outcomes, equity holders were largely wiped out; creditor-led plans typically issue new equity to creditors, reducing institutional and insider ownership percentages.
Where to find more detail
For background on strategic shifts and brand divestitures see the article on Marketing Strategy of Amyris
Amyris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Amyris Company?
- What is Competitive Landscape of Amyris Company?
- What is Growth Strategy and Future Prospects of Amyris Company?
- How Does Amyris Company Work?
- What is Sales and Marketing Strategy of Amyris Company?
- What are Mission Vision & Core Values of Amyris Company?
- What is Customer Demographics and Target Market of Amyris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.